B
Keros Therapeutics, Inc. — Earnings Quality Grade B
KROS · Healthcare
Generally healthy
Revenue
$244M
2025
Net Income
$87M
2025
Gross Margin
—
Free Cash Flow
$106M
01
Screening Summary
12
Passed
2
Watch
0
Failed
—
M-Score
管理层信号
最近 SEC 8-K 文件中未发现 CEO、CFO、董事会或审计负责人变动信号。
02
Financial Trends
Revenue & Net Income ($B)
Margins (%)
03
18-Point Screening
01
Revenue Quality
✓
A1DSO Change
DSO 5 days, change -277 days YoY
✓
A2AR vs Revenue Growth
AR growth 30.1% vs revenue growth 6775.0%
!
A3Revenue vs CFFO
Revenue grew 6775.0% but CFFO only 166.8%
02
Expense Quality
✓
B1Inventory vs COGS
No material inventory
✓
B2CapEx vs Revenue
CapEx growth -19.7% vs revenue 6775.0%. Normal
—
B3SG&A Ratio
Insufficient data
—
B4Gross Margin
Insufficient data
03
Cash Flow Quality
✓
C1CFFO vs Net Income
CFFO/NI = 1.24. Profits backed by cash
✓
C2Free Cash Flow
FCF $0.1B, FCF/NI = 1.22
✓
C3Accruals Ratio
Accruals ratio = -6.1%. Low accruals
✓
C4Cash vs Debt
Cash $0.3B covers debt $0.0B
04
Balance Sheet Health
✓
D1Goodwill + Intangibles
No goodwill. Clean balance sheet
✓
D2Leverage
Debt/EBITDA = 0.2x. Healthy
✓
D3Soft Asset Growth
Other assets -58.7% vs revenue 6775.0%. Normal
—
D4Asset Impairment
No write-off data
05
Acquisition Risk
!
E1Serial Acquirer FCF
FCF after acquisitions negative for 2/3 years
✓
E2Goodwill Surge
No goodwill
06
Manipulation Score
—
F1Beneish M-Score
Insufficient data
05
Altman Z-Score
11.55
Safe Zone0 Distress1.102.605.0+ Safe
0.8728
Liquidity
-1.4253
Cumulative profit
0.1999
Operating efficiency
8.6885
Leverage
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25